Alıntılar

APA (7. basım) Alıntı
Morgan, R. D., Porter, C., Zhou, C., Kristeleit, R., Desai, S., Vazquez, I., . . . Clamp, A. R. (2026). Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): A multicentre, open-label, randomised, phase 2 trial in the UKResearch in context. Elsevier.
Chicago Style (17. basım) Atıf
Morgan, Robert D., et al. Cediranib with Weekly Paclitaxel or Olaparib Versus Weekly Paclitaxel for Advanced or Recurrent Endometrial Cancer (COPELIA): A Multicentre, Open-label, Randomised, Phase 2 Trial in the UKResearch in Context. Elsevier, 2026.
MLA (9th ed.) Atıf
Morgan, Robert D., et al. Cediranib with Weekly Paclitaxel or Olaparib Versus Weekly Paclitaxel for Advanced or Recurrent Endometrial Cancer (COPELIA): A Multicentre, Open-label, Randomised, Phase 2 Trial in the UKResearch in Context. Elsevier, 2026.
Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..